A Woman’s Uterus Has Been Kept Alive Outside the Body for the First Time

Why It Matters

Extending uterine preservation could improve uterus‑transplant logistics and provide a live platform to study implantation, boosting IVF success and reproductive research. It also lays groundwork for future technologies that might enable gestation outside the body.

Key Takeaways

• Device kept human uterus viable for 24 hours ex‑vivo.
• Perfusion mimics blood flow using modified human blood and oxygenator.
• Longer preservation could expand deceased‑donor uterus transplant pool.
• Researchers aim for 28‑day cycle study to investigate implantation.
• Future vision includes full gestation in a lab‑based uterus.

Pulse Analysis

The breakthrough stems from the same normothermic machine‑perfusion platforms that have already transformed liver, kidney and heart transplantation. By circulating oxygenated, nutrient‑rich blood through a sealed circuit, the device—dubbed “Mother” and technically known as PUPER—maintains a donated human uterus at physiological temperature and pressure. In the Valencia laboratory, the team connected a freshly harvested uterus to the system and sustained cellular activity for a full 24 hours, a duration that far exceeds the typical two‑hour window for most organs outside the body. This proof‑of‑concept demonstrates that uterine tissue can survive ex‑vivo long enough for detailed study.

Extending uterine viability opens new avenues for both clinical transplantation and assisted‑reproductive research. At present, uterus transplants rely on living donors and a narrow time frame, limiting donor availability and increasing surgical risk. A 24‑hour preservation window would allow hospitals to retrieve organs from deceased donors, match them more carefully, and perform pre‑transplant functional testing, potentially raising success rates. Moreover, a perfused uterus can be observed throughout a simulated menstrual cycle, giving scientists unprecedented access to implantation dynamics, endometriosis, and fibroid pathology—key obstacles in IVF outcomes.

Looking ahead, the team envisions scaling the system to support a full gestation, a prospect that would redefine reproductive options for individuals lacking a functional uterus. Such a capability raises profound bioethical questions, especially regarding the use of embryo‑like structures derived from stem cells for implantation studies. Commercial interest is already emerging, with biotech firms eyeing perfusion platforms as a service for reproductive clinics and pharmaceutical testing. While a 30‑day ex‑vivo uterus remains speculative—current organ‑preservation records top seven days—the current milestone marks a pivotal step toward longer‑term uterine biobanking and, ultimately, lab‑based pregnancy research.